Cencora, Inc. (NYSE:COR) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp decreased its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 9.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 147,553 shares of the company's stock after selling 15,845 shares during the period. Van ECK Associates Corp owned 0.08% of Cencora worth $33,152,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Concord Wealth Partners acquired a new stake in shares of Cencora in the third quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Kentucky Trust Co acquired a new stake in shares of Cencora in the fourth quarter worth $33,000. Ashton Thomas Securities LLC acquired a new stake in shares of Cencora in the third quarter worth $41,000. Finally, Modus Advisors LLC acquired a new stake in shares of Cencora in the fourth quarter worth $54,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on COR shares. Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price for the company. Wells Fargo & Company upped their target price on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Robert W. Baird increased their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Stock Performance

Shares of Cencora stock traded down $2.34 during trading hours on Tuesday, reaching $240.29. The company's stock had a trading volume of 476,455 shares, compared to its average volume of 1,482,396. The company's 50 day simple moving average is $238.75 and its 200 day simple moving average is $237.41. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The stock has a market cap of $46.44 billion, a P/E ratio of 34.23, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, analysts expect that Cencora, Inc. will post 15.36 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.92%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares of the company's stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.